Gorlin syndrome, also
known as basal cell nevus syndrome, is an inherited genetic disorder
characterized by multiple basal cell skin cancer.
The common symptoms
observed during Gorlin syndrome are calcium deposition in brain, jaw cysts,
skeletal changes and developmental disability. The person with Gorlin syndrome
appears with a prominent forehead, widely spaced eyes, small skin bumps and
skin cysts.
Ascend Biopharmaceuticals Ltd. is in the process of developing ASN-002, a chemoimmunotherapy, for the treatment of Gorlin syndrome. PellePharm Inc., and F. Hoffmann-La Roche Ltd. are some other key players having drugs for Gorlin syndrome in their pipeline.
Want to know more about Gorlin Syndrome Therapeutics Pipeline request to get the sample report at: https://www.pharmaproff.com/request-sample/1113
Gorlin syndrome is
screened by neurological evaluation, dental X-Ray and measurement of head size.
The main treatment for Gorlin syndrome includes imiquimod cream, chemotherapy,
photodynamic therapy and retinoids.Ascend Biopharmaceuticals Ltd. is in the process of developing ASN-002, a chemoimmunotherapy, for the treatment of Gorlin syndrome. PellePharm Inc., and F. Hoffmann-La Roche Ltd. are some other key players having drugs for Gorlin syndrome in their pipeline.
No comments:
Post a Comment